406 related articles for article (PubMed ID: 21489024)
21. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
22. The human ether-a-go-go-related gene (hERG) current inhibition selectively prolongs action potential of midmyocardial cells to augment transmural dispersion.
Yasuda C; Yasuda S; Yamashita H; Okada J; Hisada T; Sugiura S
J Physiol Pharmacol; 2015 Aug; 66(4):599-607. PubMed ID: 26348084
[TBL] [Abstract][Full Text] [Related]
23. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
24. High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656.
Ridley JM; Milnes JT; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2004 Dec; 325(3):883-91. PubMed ID: 15541373
[TBL] [Abstract][Full Text] [Related]
25. Allosteric modulators of the hERG K(+) channel: radioligand binding assays reveal allosteric characteristics of dofetilide analogs.
Yu Z; Klaasse E; Heitman LH; Ijzerman AP
Toxicol Appl Pharmacol; 2014 Jan; 274(1):78-86. PubMed ID: 24200993
[TBL] [Abstract][Full Text] [Related]
26. Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias.
Potet F; Lorinc AN; Chaigne S; Hopkins CR; Venkataraman R; Stepanovic SZ; Lewis LM; Days E; Sidorov VY; Engers DW; Zou B; Afshartous D; George AL; Campbell CM; Balser JR; Li M; Baudenbacher FJ; Lindsley CW; Weaver CD; Kupershmidt S
J Biol Chem; 2012 Nov; 287(47):39613-25. PubMed ID: 23033485
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the effects of DC031050, a class III antiarrhythmic agent, on hERG channel and three neuronal potassium channels.
Li P; Sun HF; Zhou PZ; Ma CY; Hu GY; Jiang HL; Li M; Liu H; Gao ZB
Acta Pharmacol Sin; 2012 Jun; 33(6):728-36. PubMed ID: 22609836
[TBL] [Abstract][Full Text] [Related]
28. Interactions at human ether-à-go-go-related gene channels.
Friemel A; Zünkler BJ
Toxicol Sci; 2010 Apr; 114(2):346-55. PubMed ID: 20071423
[TBL] [Abstract][Full Text] [Related]
29. [3H]dofetilide binding in SHSY5Y and HEK293 cells expressing a HERG-like K+ channel?
Finlayson K; Pennington AJ; Kelly JS
Eur J Pharmacol; 2001 Feb; 412(3):203-12. PubMed ID: 11166283
[TBL] [Abstract][Full Text] [Related]
30. Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells.
Zhao J; Wang Q; Xu J; Zhao J; Liu G; Peng S
Eur J Pharmacol; 2011 Jun; 660(2-3):259-67. PubMed ID: 21497594
[TBL] [Abstract][Full Text] [Related]
31. Block of HERG-carried K+ currents by the new repolarization delaying agent H 345/52.
Amos GJ; Jacobson I; Duker G; Carlsson L
J Cardiovasc Electrophysiol; 2003 Jun; 14(6):651-8. PubMed ID: 12875428
[TBL] [Abstract][Full Text] [Related]
32. Facilitation of
Furutani K; Tsumoto K; Chen IS; Handa K; Yamakawa Y; Sack JT; Kurachi Y
J Gen Physiol; 2019 Feb; 151(2):214-230. PubMed ID: 30674563
[TBL] [Abstract][Full Text] [Related]
33. Assessment of temperature-induced hERG channel blockade variation by drugs.
Kauthale RR; Dadarkar SS; Husain R; Karande VV; Gatne MM
J Appl Toxicol; 2015 Jul; 35(7):799-805. PubMed ID: 25348819
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide.
Paul AA; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2001 Feb; 280(5):1243-50. PubMed ID: 11162661
[TBL] [Abstract][Full Text] [Related]
35. Dimethyl sulfoxide effects on hERG channels expressed in HEK293 cells.
Du X; Lu D; Daharsh ED; Yao A; Dewoody R; Yao JA
J Pharmacol Toxicol Methods; 2006; 54(2):164-72. PubMed ID: 16782359
[TBL] [Abstract][Full Text] [Related]
36. The evolutionarily conserved residue A653 plays a key role in HERG channel closing.
Stepanovic SZ; Potet F; Petersen CI; Smith JA; Meiler J; Balser JR; Kupershmidt S
J Physiol; 2009 Jun; 587(Pt 11):2555-66. PubMed ID: 19406877
[TBL] [Abstract][Full Text] [Related]
37. Proton block of the pore underlies the inhibition of hERG cardiac K+ channels during acidosis.
Van Slyke AC; Cheng YM; Mafi P; Allard CR; Hull CM; Shi YP; Claydon TW
Am J Physiol Cell Physiol; 2012 Jun; 302(12):C1797-806. PubMed ID: 22517356
[TBL] [Abstract][Full Text] [Related]
38. Enhanced inhibitory effect of acidosis on hERG potassium channels that incorporate the hERG1b isoform.
Du CY; El Harchi A; McPate MJ; Orchard CH; Hancox JC
Biochem Biophys Res Commun; 2011 Feb; 405(2):222-7. PubMed ID: 21219869
[TBL] [Abstract][Full Text] [Related]
39. Dofetilide block involves interactions with open and inactivated states of HERG channels.
Weerapura M; Hébert TE; Nattel S
Pflugers Arch; 2002 Feb; 443(4):520-31. PubMed ID: 11907818
[TBL] [Abstract][Full Text] [Related]
40. Blockade of HERG K+ channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656.
Park SJ; Kim KS; Kim EJ
J Appl Toxicol; 2008 Mar; 28(2):104-11. PubMed ID: 17516459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]